Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03899064 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream
A Phase 1 study, sponsored by MC2 Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT03899064: Completed Phase 1 study, sponsored by MC2 Therapeutics.
NCT03899064 is a Phase 1 study that has completed, run by MC2 Therapeutics. The registered enrollment target is 58 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03899064, a Phase 1 study, has completed, sponsored by MC2 Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
This trial is a 6-week, Randomized study evaluating the potential of MC2-01 Cream to induce a photoallergic skin reaction in Healthy subjects, using a controlled photopatch test design.
Primary Outcome
After an induction phase, where subjects were treated with MC2-01 Cream, MC2-01 vehicle and irradiation, the challenge phase was initiated. MC2-01 Cream and MC2-01 vehicle was applied to each two naive test sites. Another naive test site was untreated. 24 hours after product application, one of each test site (MC2-01 Cream, MC2-01 vehicle) + the untreated site were irradiated. Possible changes in dermal reaction (erythema and edema) was evaluated at all 5 test sites 24, 48 and 72 hours post-irr
Interventions
- DRUG Induction: Application of MC2-01 Cream, irradiation
- DRUG Induction: Application of MC2-01 Cream, no irradiation
- DRUG Induction: Applications of MC2-01 vehicle, irradiation
- DRUG Induction: Applications of MC2-01 vehicle, no irradiation
- DRUG Challenge: Application of MC2-01 Cream, irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2019-02-13 |
| Est. Completion | 2019-04-05 |
| Phase | Phase 1 |
What the finished NCT03899064 record still lists
NCT03899064 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Induction: Application of MC2-01 Cream, irradiation is the first listed.
NCT03899064 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03899064 about?
NCT03899064 is a clinical study titled "Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream". This trial is a 6-week, Randomized study evaluating the potential of MC2-01 Cream to induce a photoallergic skin reaction in Healthy subjects, using a controlled photopatch test design.
What is the current status of trial NCT03899064?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2019-02-13. Estimated completion is 2019-04-05.
What interventions are being tested in trial NCT03899064?
The interventions under investigation include: Induction: Application of MC2-01 Cream, irradiation (DRUG), Induction: Application of MC2-01 Cream, no irradiation (DRUG), Induction: Applications of MC2-01 vehicle, irradiation (DRUG), Induction: Applications of MC2-01 vehicle, no irradiation (DRUG), Challenge: Application of MC2-01 Cream, irradiation (DRUG).
Who is sponsoring clinical trial NCT03899064?
This trial is sponsored by MC2 Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03899064's enrollment target sits among peer trials
58 895th of 2000 higher than 1,100 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI